OS Therapies IncOSTX
Price$1.61

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$39.4MTTM through 30 Jun 2026
Free Cash Flow -$19MTTM through 30 Jun 2026

Margins

Current
Gross Margin0.0%

Returns

330.4%ROE

Balance Sheet Health

Debt / Equity0.00x
Current Ratio0.03x
Net Debt$1M
Cash & Equivalents$205K

Quality Metrics

Altman Z-Score-24.40
Piotroski F-Score2 / 9
Earnings-Beat Rate0.0%

Multi-Year Trend

Diluted EPS-$1.09TTM
'24'25
FY2025: $-0.98

Dividend

No dividend

Capital Allocation

R&D Spend$26M

Segment Performance

SegmentRevenueYoYOutlook
Oncology Therapeutics$0
View details

Preparing for rolling BLA submission to the FDA and conditional MAA filings in the UK and Europe.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.